Dyne Therapeutics (NASDAQ:DYN) Director Brian Posner Acquires 2,500 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner acquired 2,500 shares of the stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $17.12 per share, for a total transaction of $42,800.00. Following the completion of the purchase, the director directly owned 18,000 shares in the company, valued at $308,160. The trade was a 16.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock remained flat at $17.37 during trading on Friday. 1,448,061 shares of the stock traded hands, compared to its average volume of 2,008,177. The firm has a market cap of $2.87 billion, a PE ratio of -5.39 and a beta of 1.08. The stock has a fifty day moving average of $18.33 and a two-hundred day moving average of $18.40. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the business earned ($1.05) EPS. Equities research analysts forecast that Dyne Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Sanford C. Bernstein lifted their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Institutional Trading of Dyne Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in DYN. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after acquiring an additional 14,727,667 shares during the period. Orbis Allan Gray Ltd bought a new stake in shares of Dyne Therapeutics during the 4th quarter worth approximately $93,926,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Dyne Therapeutics during the 2nd quarter worth approximately $30,378,000. Perceptive Advisors LLC lifted its holdings in shares of Dyne Therapeutics by 543.7% during the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after acquiring an additional 2,938,500 shares during the period. Finally, Marshall Wace LLP lifted its holdings in shares of Dyne Therapeutics by 572.9% during the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after acquiring an additional 2,565,570 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.